North America Pancreatic Cancer Diagnostic Market size to reach USD 2.1 Billion by 2034

Selbyville, DE. - North America pancreatic cancer diagnostic market was estimated at USD 1.1 billion in 2024 and is expected to reach USD 2.1 billion in 2034, at a CAGR of 7%, according to the latest report published by Global Market Insights Inc.

Pancreatic cancer cases are increasing in the U.S. and Canada due to aging populations, obesity, diabetes, and lifestyle factors like smoking. This drives greater demand for diagnostic tools to enable earlier detection and treatment planning.

Key Insights:

Market Size & Growth:

• 2024 Market Size: USD 1.1 billion
  
• 2034 Forecast Market Size: USD 2.1 billion
  
• CAGR (2025–2034): 7%
  

• Regional Insights:

• Largest Market: U.S
  
• Fastest Growing Market: Canada
  

• Key Growth Drivers:

1. Need for early diagnosis: Pancreatic cancer often shows symptoms only in later stages, leading to poor survival rates.
   
2. Technological advancements in diagnostics: Innovations in imaging (CT, MRI, endoscopic ultrasound), molecular diagnostics (e.g., next-gen sequencing), liquid biopsy, and AI-based tools are enhancing accuracy and speed of diagnosis, making adoption more attractive to providers.
   
3. High healthcare spending and infrastructure: North America has one of the world’s most advanced healthcare systems with strong investment in diagnostic infrastructure, clinical research, and availability of specialized diagnostic labs, supporting market growth.
   
4. Favorable reimbursement and regulatory support: Diagnostic tools, particularly those approved by the FDA and covered by insurance, have a clearer path to adoption.
   
5. Growth of precision and personalized medicine: There is a growing emphasis on tailoring cancer treatment to individual patient profiles. This increases the demand for diagnostic tools that can identify genetic mutations, tumor subtypes, and predictive biomarkers for targeted therapies.
   

• Key Players:

• GE Healthcare led the market with over 18% share in 2024.
  
• Some of the top players in this market include Thermo Fisher Scientific, Koninklijke Philips, GE Healthcare, F. Hoffmann La Roche, and Siemens Healthineers, which together held a 62% share in 2024.
  

• Key Challenges

1. Late detection and asymptomatic progression: Pancreatic cancer often progresses without symptoms, making early diagnosis difficult and reducing the effectiveness of most diagnostic tools.
   
2. Lack of reliable early biomarkers: There is still a major gap in validated, non-invasive biomarkers specific to early-stage pancreatic cancer, limiting early detection capabilities.
   
3. High cost of advanced diagnostic technologies: Molecular testing, high-end imaging, and liquid biopsies can be expensive, limiting accessibility, especially in underinsured or rural populations.
   
4. Limited screening programs: Unlike other cancers (e.g., breast or colon), there are no widespread screening protocols or guidelines for pancreatic cancer in asymptomatic individuals.
   
5. Regulatory and reimbursement hurdles: New diagnostic tools face strict FDA requirements and may struggle to get favorable reimbursement, delaying market entry and adoption.
   

Browse key industry insights spread across 90 pages with 41 market data tables and figures from the report, “North America Pancreatic Cancer Diagnostic Market - By Product, By Test Type, By Cancer Type, By End Use - Regional Forecast, 2025 - 2034” in detail, along with the table of contents:

https://www.gminsights.com/industry-analysis/north-america-pancreatic-cancer-diagnostic-market

Increasing Demand for Consumables

The consumables segment held a significant share in 2024, driven by the recurring demand for reagents, assay kits, and other testing supplies. These items are essential for both molecular and immunoassay-based diagnostic procedures. As laboratories and diagnostic centers perform a growing number of tests due to rising pancreatic cancer incidence, the need for high-quality, reliable consumables continues to surge.

Rising Prevalence of Imaging Test

The imaging tests segment generated a substantial share in 2024, fueled by initial detection and staging. Techniques such as endoscopic ultrasound (EUS), computed tomography (CT), and magnetic resonance imaging (MRI) offer detailed visualization of the pancreas and surrounding structures. The imaging test segment in North America is evolving with the integration of advanced technologies like AI-enhanced image analysis and hybrid imaging modalities that combine structural and functional data.

Exocrine to Gain Traction

The exocrine segment held a robust share in 2024, owing to the majority of pancreatic cancers, specifically adenocarcinomas. This segment is marked by aggressive disease progression and limited treatment windows, which heightens the need for prompt and accurate diagnostics. Companies focusing on the exocrine segment are investing in developing tests that can detect cancer at the earliest possible stage, often through genetic profiling, protein biomarkers, and tissue-based assays.

U.S. to Emerge as a Propelling Region

United States pancreatic cancer diagnostic market will grow at a decent CAGR during 2025-2034. High disease prevalence, strong healthcare infrastructure, and a culture of early diagnosis contribute to its dominant position. The U.S. market is characterized by robust investments in research and development, favorable reimbursement policies, and widespread adoption of advanced diagnostic platforms. Hospitals and specialized cancer centers increasingly use multi-modal diagnostic approaches, integrating imaging, molecular testing, and AI-based tools.

Major players in the North America pancreatic cancer diagnostic market are Danaher Corporation, Myriad Genetics, GE Healthcare, Canon, Illumina, Siemens Healthineers, Thermo Fisher Scientific, Agilent Technologies, F. Hoffmann-La Roche, Becton, Dickinson and Company, QIAGEN, Abbott Laboratories, Sysmex Corporation, Boston Scientific Corporation, and Koninklijke Philips.

To strengthen their market presence, companies operating in the North American pancreatic cancer diagnostic landscape are adopting a multi-pronged strategy. This includes expanding product portfolios through mergers, acquisitions, and licensing deals to integrate new technologies and platforms. Strategic collaborations with academic institutions and cancer research centers are helping to accelerate innovation and clinical validation. Many firms are also prioritizing FDA approvals and compliance with evolving regulatory standards to ensure faster time-to-market. Furthermore, companies are investing in artificial intelligence and machine learning to enhance diagnostic accuracy, while also rolling out comprehensive training programs to support clinical adoption.